A detailed history of Morgan Stanley transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Morgan Stanley holds 130,598 shares of MLTX stock, worth $6.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130,598
Previous 69,027 89.2%
Holding current value
$6.81 Million
Previous $3.04 Million 116.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.15 - $55.4 $2.47 Million - $3.41 Million
61,571 Added 89.2%
130,598 $6.58 Million
Q2 2024

Oct 17, 2024

SELL
$38.43 - $48.6 $6.15 Million - $7.78 Million
-160,155 Reduced 69.88%
69,027 $3.04 Million
Q2 2024

Aug 14, 2024

SELL
$38.43 - $48.6 $6.15 Million - $7.78 Million
-160,155 Reduced 69.88%
69,027 $3.04 Million
Q1 2024

Oct 17, 2024

BUY
$43.78 - $63.86 $7.01 Million - $10.2 Million
160,155 Added 232.02%
229,182 $11.5 Million
Q1 2024

Aug 16, 2024

BUY
$43.78 - $63.86 $7.12 Million - $10.4 Million
162,668 Added 244.56%
229,182 $11.5 Million
Q1 2024

May 15, 2024

BUY
$43.78 - $63.86 $7.12 Million - $10.4 Million
162,668 Added 244.56%
229,182 $11.5 Million
Q4 2023

Aug 16, 2024

SELL
$36.35 - $63.02 $91,347 - $158,369
-2,513 Reduced 3.64%
66,514 $4.02 Million
Q4 2023

Feb 13, 2024

BUY
$36.35 - $63.02 $2.07 Million - $3.6 Million
57,063 Added 603.78%
66,514 $4.02 Million
Q3 2023

Nov 15, 2023

SELL
$48.35 - $61.26 $7.25 Million - $9.19 Million
-149,974 Reduced 94.07%
9,451 $538,000
Q2 2023

Aug 14, 2023

BUY
$19.01 - $51.79 $2.41 Million - $6.57 Million
126,906 Added 390.25%
159,425 $8.13 Million
Q1 2023

May 15, 2023

BUY
$11.03 - $23.7 $56,848 - $122,149
5,154 Added 18.83%
32,519 $695,000
Q4 2022

Feb 14, 2023

BUY
$7.05 - $10.5 $171,068 - $254,782
24,265 Added 782.74%
27,365 $287,000
Q3 2022

Nov 14, 2022

BUY
$5.25 - $9.27 $16,275 - $28,737
3,100 New
3,100 $24,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.93B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.